Sign In
Buy PCRX
$22.32
+0.0700 (+0.315%)
At Close: Jun 03, 2026
Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Pacira BioSciences, Inc. (PCRX)
11:35am, Tuesday, 14'th Jan 2025
NEW YORK, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of New Jersey
NEW YORK, NY / ACCESSWIRE / January 14, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
NEW YORK CITY, NY / ACCESSWIRE / January 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira B
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers or acquirers of securities of Pacira BioScie
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / If you suffered a loss on your Pacira BioSciences, Inc. (NASDAQ:PCRX) investment and want to learn about a potential recovery under the federal securitie
NEW YORK CITY, NY / ACCESSWIRE / January 13, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Pacira B
NEW YORK, Jan. 13, 2025 (GLOBE NEWSWIRE) -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Pacira BioSc
PCRX Stock Rises 11% on Upbeat Q4 Preliminary Product Sales
12:45pm, Monday, 13'th Jan 2025
Pacira stock gains 11% on better-than-expected preliminary Q4 sales figures. It also shares a strategic growth plan to drive innovation and value creation by 2030.
Pacira (PCRX) Soars 11.1%: Is Further Upside Left in the Stock?
10:25am, Monday, 13'th Jan 2025
Pacira (PCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Investors who lost money on Pacira BioSciences, Inc. should contact Levi & Korsinsky about an ongoing investigation - PCRX
07:30am, Monday, 13'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 13, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concern
Lost Money on Pacira BioSciences, Inc. (PCRX)? You May Have Been Affected by Fraud - Contact Levi & Korsinsky
07:30am, Friday, 10'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 10, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concern
Lost Money on Pacira BioSciences, Inc. (PCRX)? Contact Levi & Korsinsky Regarding an Ongoing Investigation
07:30am, Thursday, 09'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 9, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerni
FDA Clears PCRX's New Iovera Smart Tip for Expanded Use in Pain Relief
12:21pm, Wednesday, 08'th Jan 2025
Pacira receives FDA approval for a new iovera Smart Tip aimed at expanding pain management capabilities to deeper nerves like the medial branch nerve.
Pacira BioSciences, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - PCRX
07:25am, Wednesday, 08'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 8, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerni
Pacira BioSciences, Inc. Being Investigated on Behalf of Pacira BioSciences, Inc. Investors. Contact Levi & Korsinsky For Details.
07:25am, Tuesday, 07'th Jan 2025
NEW YORK, NY / ACCESSWIRE / January 7, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pacira BioSciences, Inc. ("Pacira BioSciences, Inc.") (NASDAQ:PCRX) concerni
